Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumor… Read more
Bicara Therapeutics Inc. Common Stock (BCAX) - Net Assets
Latest net assets as of September 2025: $402.78 Million USD
Based on the latest financial reports, Bicara Therapeutics Inc. Common Stock (BCAX) has net assets worth $402.78 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($424.69 Million) and total liabilities ($21.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $402.78 Million |
| % of Total Assets | 94.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Bicara Therapeutics Inc. Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how Bicara Therapeutics Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bicara Therapeutics Inc. Common Stock (2022–2024)
The table below shows the annual net assets of Bicara Therapeutics Inc. Common Stock from 2022 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $491.88 Million | +125.11% |
| 2023-12-31 | $218.51 Million | +1364.66% |
| 2022-12-31 | $-17.28 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bicara Therapeutics Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 11998000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.00K | 0.00% |
| Other Components | $712.88 Million | 144.93% |
| Total Equity | $491.88 Million | 100.00% |
Bicara Therapeutics Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Bicara Therapeutics Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INMODE LTD IS -01
F:154
|
$681.19 Million |
|
Heineken Bhd
KLSE:3255
|
$681.30 Million |
|
NFI Group Inc
PINK:NFYEF
|
$681.44 Million |
|
TFS Financial Corporation
NASDAQ:TFSL
|
$681.60 Million |
|
Deutsche Pfandbriefbank AG
OTCGREY:PBBGF
|
$681.08 Million |
|
KODIAK SCIENCES DL-0001
F:K27
|
$681.04 Million |
|
Sigma Lithium Resources Corp
NASDAQ:SGML
|
$680.96 Million |
|
Fox Factory Holding Corp
NASDAQ:FOXF
|
$680.61 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bicara Therapeutics Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 218,508,000 to 491,875,000, a change of 273,367,000 (125.1%).
- Net loss of 67,995,000 reduced equity.
- New share issuances of 332,427,000 increased equity.
- Other factors increased equity by 8,935,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-68.00 Million | -13.82% |
| Share Issuances | $332.43 Million | +67.58% |
| Other Changes | $8.94 Million | +1.82% |
| Total Change | $- | 125.11% |
Book Value vs Market Value Analysis
This analysis compares Bicara Therapeutics Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.14x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $-0.33 | $19.32 | x |
| 2023-12-31 | $4.22 | $19.32 | x |
| 2024-12-31 | $9.04 | $19.32 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bicara Therapeutics Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -13.82%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.16x
- Recent ROE (-13.82%) is below the historical average (-12.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.12 Million |
| 2023 | -23.79% | 0.00% | 0.00x | 1.07x | $-73.84 Million |
| 2024 | -13.82% | 0.00% | 0.00x | 1.16x | $-117.18 Million |
Industry Comparison
This section compares Bicara Therapeutics Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bicara Therapeutics Inc. Common Stock (BCAX) | $402.78 Million | 0.00% | 0.05x | $681.15 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |